Detalhe da pesquisa
1.
Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing.
Nature;
574(7779): 553-558, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31645721
2.
Assessment of Mammalian Target of Rapamycin Pathway Activation in Basal Cell Carcinoma as a New Therapeutic Approach.
Am J Dermatopathol;
2024 Apr 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38648034
3.
Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.
J Am Acad Dermatol;
88(6): 1243-1255, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37268391
4.
Immunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers.
J Am Acad Dermatol;
88(6): 1225-1240, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37268390
5.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol;
22(6): 848-857, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34000246
6.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med;
379(4): 341-351, 2018 07 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29863979
7.
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Lancet Oncol;
21(2): 294-305, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31952975
8.
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
J Am Acad Dermatol;
90(2): 414-418, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37839734
9.
An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea.
Br J Dermatol;
189(6): 776-778, 2023 11 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37596936
10.
Evidence-based update on rosacea comorbidities and their common physiologic pathways.
J Am Acad Dermatol;
78(1): 156-166, 2018 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29089181
11.
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
J Am Acad Dermatol;
79(6): 1047-1052, 2018 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29857011
12.
A daily skincare regimen with a unique ceramide and filaggrin formulation rapidly improves chronic xerosis, pruritus, and quality of life in older adults.
Geriatr Nurs;
39(1): 24-28, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28600081
13.
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
J Am Acad Dermatol;
75(1): 113-125.e5, 2016 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27067394
14.
Estimation of individual cumulative ultraviolet exposure using a geographically-adjusted, openly-accessible tool.
BMC Dermatol;
16: 1, 2016 Jan 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26790927
15.
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Lancet Oncol;
16(6): 716-28, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25981810
16.
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
N Engl J Med;
366(23): 2171-9, 2012 Jun 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22670903
17.
The role of the dermatologist in detecting elder abuse and neglect.
J Am Acad Dermatol;
73(2): 285-93, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25956658
18.
A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis.
J Am Acad Dermatol;
83(6): 1807-1809, 2020 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32289388
19.
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
J Am Acad Dermatol;
72(6): 1021-6.e8, 2015 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25981002
20.
Reply to: "Use of immortal time within survival analysis".
J Am Acad Dermatol;
80(1): e19-e20, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30205131